DOI QR코드

DOI QR Code

Systematic Analysis of Pemetrexed-based Chemoradiotherapy for Patients with Locally Advanced or Metastatic Esophageal Cancer

  • Tian, Guang-Yu (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Miu, Min (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
  • Published : 2014.10.23

Abstract

Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of pemetrexed-based chemoradiotherapy in treating patients with locally advanced or metastatic esophageal cancer. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for relevant patients were identified using a predefined search strategy. Pooled response rates (RRs) were calculated. Results: For pemetrexed-based regimens, 4 clinical studies including 47 patients with locally advanced or metastatic esophageal cancer were considered eligible for inclusion. Systematic analysis showed that, in all patients, the pooled RR was 51% (24/47). Major adverse effects of grade III/IV were esophagitis, neutropenia, thrombocytopenia, anemia anorexia, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-based treatment. Conclusion: This systematic analysis suggests that pemetrexed based radiotherapy is associated with reasonable activity and good tolerability in treating patients with locally advanced or metastatic esophageal cancer.

Keywords

References

  1. Ajani JA, Ilson DH, Daugherty K, et al (1994). Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst, 86, 1086-91. https://doi.org/10.1093/jnci/86.14.1086
  2. Bhatt RS, Merchan J, Parker R, et al (2010). A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 116, 1751-6. https://doi.org/10.1002/cncr.24902
  3. Bucci MK, Rosenthal DI, Hershock D, et al (2004). Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol, 27, 595-602. https://doi.org/10.1097/01.coc.0000135738.85334.ed
  4. Herscher LL, Cook J (1999). Taxanes as radiosensitizers for head and neck cancer. Curr Opin Oncol, 11, 183-6. https://doi.org/10.1097/00001622-199905000-00008
  5. Holmes FA, Valero V, Buzdar AU (1998). Final results: randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer: the long and the short of it. Proc Am Soc Clin Oncol, 17, 110a (Abstr 426).
  6. Jatoi A, Soori G, Foster NR, et al (2010). Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol, 5, 1994-8. https://doi.org/10.1097/JTO.0b013e3181fb5c3e
  7. Katipamula R, Jatoi A, Foster NR, et al (2008). Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E. Clin Med Oncol, 2, 223-5.
  8. Kelsey CR, Chino JP, Willett CG, et al (2007). Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys, 69, 770-6. https://doi.org/10.1016/j.ijrobp.2007.03.035
  9. Langer CJ, Harris J, Horwitz EM, et al (2007). Phase II study of low-dose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25, 4800-5. https://doi.org/10.1200/JCO.2006.07.9194
  10. Li BS, Gong HY, Huang W, et al (2011). Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus, b, 251-7.
  11. Liu JL, Zhou LL, Cai MH, et al (2009). Observation on the short-term effect of nedaplatin plus tegafur in the treatment of advanced esophageal carcinoma. J Pract Oncol, 24, 515-6.
  12. Jiang C, Liao FX, Rong YM, et al (2014). Efficacy of taxanebased regimens in a first-line setting for recurrent and/or metastatic Chinese patients with esophageal cancer. Asian Pac J Cancer Prev, 15, 5493-8. https://doi.org/10.7314/APJCP.2014.15.13.5493
  13. Mirinezhad SK, Somi MH, Jangjoo AG, et al (2012). Survival rate and prognostic factors of esophageal cancer in east Azerbaijan province, North-west of Iran. Asian Pac J Cancer Prev, 13, 3451-4. https://doi.org/10.7314/APJCP.2012.13.7.3451
  14. Orditura M, Galizia G, Napolitano V, et al (2010). Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest, 28, 820-7. https://doi.org/10.3109/07357901003630926
  15. Polee MB, Eskens FA, van der Burg ME, et al (2002). Phase II study of biweeklyadministration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer, 86, 669-73. https://doi.org/10.1038/sj.bjc.6600166
  16. Safran H, Dipetrillo T, Akerman P, et al (2007). Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys, 67, 405-9. https://doi.org/10.1016/j.ijrobp.2006.08.076
  17. Seidman AD, Hochhauser D, Gollub M, et al (1996). Ninetysix hour paclitaxel infusion after progression during taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol, 14, 1877-84.
  18. Seiwert TY, Connell PP, Mauer AM, et al (2007). A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res, 13, 515-22. https://doi.org/10.1158/1078-0432.CCR-06-1058
  19. Shade RJ, Pisters KM, Huber MH, et al (1998-1999). Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs, 16, 237-43.
  20. Tang WR1, Fang JY, Wu KS, et al (2014). Epidemiological characteristics and prediction of esophageal cancer mortality in China from 1991 to 2012. Asian Pac J Cancer Prev, 15, 6929-34. https://doi.org/10.7314/APJCP.2014.15.16.6929
  21. Tsuya A, Kaneda K, Okano S, et al (1968). Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer. Gan No Rinsho, 14, 340-52.
  22. Wang J, Yu JM, Jing SW, et al (2014). Relationship between EGFR over-expression and clinicopathologic characteristics in squamous cell carcinoma of the esophagus, a metaanalysis. Asian Pac J Cancer Prev, 15, 5889-93. https://doi.org/10.7314/APJCP.2014.15.14.5889
  23. Wang T, Zhang SF, Wang L (2010). A 24-hour continuous infusion of paclitaxel in the treatment of advanced esophageal cancer. Nat Med J China, 90, 1986-8.
  24. Wei GL, Huang XE, Huo JG, et al (2013). Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. Asian Pac J Cancer Prev, 14, 2703-6. https://doi.org/10.7314/APJCP.2013.14.5.2703
  25. West HL, Crowley JJ, Vance RB, et al (2005). Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714) : a Southwest Oncology Group study. Ann Oncol, 16, 1076-80. https://doi.org/10.1093/annonc/mdi215
  26. Wong R, Malthaner R (2003). Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev, 1, CD002092.

Cited by

  1. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  2. Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1111
  3. Clinical Investigation in Effect of Riboflavin Sodium Phosphate on Prevention and Treatment for Patients with Radiotherapy Related Esophagitis vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1525
  4. Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3425
  5. Pemetrexed in Treating Patients with Metastatic Bladder Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3839
  6. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma vol.76, pp.4, 2015, https://doi.org/10.1007/s00280-015-2854-0
  7. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  8. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485